Clinical Trials | Competitor Strategies

Highlights in this white paper include:

Understanding competitor drug development strategies is critical to maximizing R&D investment. While looking at the number of drugs in development in competitors’ pipelines is a good starting point, much more granular analyses are needed to fully understand what is happening in the industry, and with competitors, specifically. This paper provides insights into which companies are sponsoring cancer trials, using data from Citeline’s Trialtrove^® and Pharmaprojects^® Pipeline^®.

A breakdown of industry-sponsored oncology trials begun between 2006-2010
Trends in industry-sponsored trials started in low resource countries
A look at trial activity by geographic area at the company level to assess competitive experience by region
Phase II and III oncology trials started with first-line patients over a five-year period

Factors contributing to country selection and patient segment, and what the trial counts show